[Design of human liposomal recombinant alpha2-interferon-containing preparation].
The composition of liposomal lipid phase preparation was selected. The optimum ratio of liposomal lipid phase components was found to produce a a human liposomal recombinant alpha 2-interferon-containing preparation by extrusion across the polycarbonate membranes. The study gave rise to a lyophilized sterile liposomal recombinant alpha 2-interferon preparation. The agent was shown to be stable and retains its antiviral activity within a year.
Zolin
V V
VV
Kolokol'tsov
A A
AA
Agafonova
O A
OA
Bochkova
T G
TG
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D004337:Drug Carriers; D015195:Drug Design; D015507:Drugs, Investigational; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D008081:Liposomes; D011994:Recombinant Proteins; D014777:Virus Diseases / Q000188:drug therapy
D000276:Adjuvants, Immunologic; D004337:Drug Carriers; D015507:Drugs, Investigational; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008081:Liposomes; D011994:Recombinant Proteins; D007372:Interferons